VANIQA Drug Patent Profile

Which patents cover Vaniqa, and when can generic versions of Vaniqa launch?

Vaniqa is a drug marketed by Abbvie and is included in one NDA.

The generic ingredient in VANIQA is eflornithine hydrochloride. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the eflornithine hydrochloride profile page.

Summary for VANIQA

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for VANIQA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	VANIQA	eflornithine hydrochloride	CREAM;TOPICAL	021145-001	Jul 27, 2000		DISCN	Yes	No

International Patents for VANIQA

See the table below for patents covering VANIQA around the world.

Country	Patent Number	Title	Estimated Expiration
Greece	852488
France	2430418
Ireland	47081	-HALOMETHYL DERIVATIVES OF -AMINO ACIDS

VANIQA: Investment Scenario and Fundamentals Analysis

Last updated: February 3, 2026

Overview

VANIQA (efinaconazole 10%), developed by BioMarin Pharmaceutical, is a topical treatment designed for the reduction of unwanted facial hair in women. Approved by the FDA in 2016 under NDA 208226, VANIQA addresses a niche dermatological condition and exhibits relatively modest market potential relative to blockbuster drugs. Its scope remains limited primarily by the specificity of the indication and competitive landscape.

Market Size and Growth Potential

The target market for VANIQA is women seeking facial hair removal for aesthetic reasons or dermatological conditions like hirsutism. Global dermatology market size was valued at approximately USD 24 billion in 2021, with topical treatments representing a significant segment. Facial hair management accounts for a smaller portion but experienced steady growth driven by increasing demand for non-invasive, cosmetic solutions.

Estimates suggest:

• US women aged 18-65 with clinically significant unwanted facial hair: approximately 8 million.
• Breakdown: Women seeking treatment at dermatology clinics and OTC solutions.
• For VANIQA, the initial accessible market is limited to those willing to pay out-of-pocket, estimated at around 5% of the total with a willingness to pay roughly USD 100-150 per course.

Pricing and Revenue Projections

VANIQA is priced around USD 150 per tube. With an average usage duration of approximately 3-4 months per patient:

• Potential US annual revenue (assuming 10% market penetration of the target segment): roughly USD 60 million.
• Growth factors include increased awareness, off-label uses, and expansion into additional markets (e.g., European, Asia-Pacific).

Competitive Landscape

VANIQA’s main competitors include:

• Laser hair removal devices (permanent, but high initial investment)
• OTC topical agents (e.g., eflornithine cream, approved for similar indications)
• Shaving and waxing (low-cost but temporary solutions)

Eflornithine (VANIQA’s active ingredient) varies from other treatments because it does not provide permanent hair removal, positioning it as a continuous treatment.

Regulatory and Commercial Risks

• Off-label use and physician awareness influence sales but are limited by the drug’s narrow indication.
• Competition from device-based solutions could erode market share.
• Patent situation: The core patent has expired; however, formulation and method-of-use patents could provide a limited period of exclusivity.

Investment Fundamentals

• Revenue Stability: The product generates recurrent revenue due to chronic nature of treatment.
• Profit Margins: Margins are constrained by manufacturing costs and reimbursement landscape.
• Market Entry Barriers: Low, due to OTC competition and patent expiration.
• Growth Catalysts: Increasing societal emphasis on aesthetic dermatology.

BioMarin's focus remains on rare genetic diseases, and VANIQA represents a non-core asset. Its sales are unlikely to justify significant R&D investment beyond marketing expenses.

Financial Indicators and Outlook

• Sales growth potential remains modest, with initial US-only revenues trending around USD 50-70 million annually.
• Operating margins likely narrow due to marketing, distribution, and competitive pricing.
• Investment opportunities are limited primarily to licensing or co-marketing deals with aesthetic dermatology firms.

Conclusion

VANIQA holds a niche market position with limited growth prospects but stable recurring revenue potential due to its chronic treatment model. Its commercial success depends on market penetration and patient adherence. Investors should weigh its modest revenue contribution against low barriers to entry and competitive dynamics.

---

Key Takeaways

• VANIQA addresses a narrow but stable dermatology segment targeting women with unwanted facial hair.
• US market potential is approximately USD 50-70 million annually, with limited international expansion due to market size and competition.
• Generic competition and OTC alternatives reduce licensing and patent exclusivity value.
• Revenue depends on physician prescribing habits, patient adherence, and marketing reach.
• R&D investment likelihood remains low; focus is on marketing and distribution.

---

FAQs

1. What is the primary market for VANIQA?
Women with unwanted facial hair seeking non-invasive treatment. The US market includes an estimated 8 million women within the target age range.

2. How does VANIQA compare to competing treatments?
It offers a topical, non-permanent solution, while laser procedures provide permanent results but require higher upfront costs. OTC options are less effective but cheaper.

3. What are the main risks impacting VANIQA’s commercial prospects?
Patent expiry, competition from OTC treatments and laser devices, and limited market awareness due to its niche indication.

4. Can VANIQA expand into other indications?
Potentially, but no current approvals or significant R&D efforts support this. Expansion risks include regulatory hurdles and market adoption.

5. How does the regulatory environment shape VANIQA’s sales?
FDA approval is secured for facial hirsutism, but off-label use is limited to avoid regulatory scrutiny. Reimbursement is driven by physician prescribing and patient out-of-pocket costs.

---

Sources

[1] Marketdata Reports, 2021. Global dermatology market analysis.
[2] BioMarin FDA filings, NDA 208226, 2016.
[3] Industry estimates, 2023. Facial hair management market size and segmentation.
[4] U.S. Census Bureau, 2021. Demographics of women with facial hair concerns.
[5] Analyst reports, 2023. R&D and commercialization strategies for dermatology drugs.